Drugmakers and other companies in the life sciences industry seeking to invalidate patents have another arrow in their quiver thanks to a recent federal court decision. In late March, the U.S. Court ...

The Federal Trade Commission (FTC) is continuing to pursue pharmaceutical manufacturers for allegedly improperly listing patents in the “Orange Book,” delaying the entry of generic drug competitors.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative ...

Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the patent covering Rezdiffra™ (resmetirom), the only FDA-approved treatment for ...